U.S., Aug. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07785206) titled 'Effectiveness of Saccharomyces Boulardii in Prevention of Antibiotic Associated Diarrhea' on Aug. 20.
Brief Summary: Antibiotic-associated diarrhea (AAD) is a common adverse effect in pediatric patients receiving broad-spectrum antibiotics such as co-amoxiclav for upper respiratory tract infections (URTI). This study aims to evaluate the effectiveness of the probiotic Saccharomyces boulardii in preventing antibiotic-associated diarrhea among children aged 6 months to 5 years receiving co-amoxiclav. Participants will be randomly allocated to receive either standard co-amoxiclav therapy alone or co-amoxiclav combined with Saccharomyce...